Skip to main content
OpenTrials
Completed

NCT Number: NCT03698071

Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis

The study aims at defining the role of soluble CD95 Ligand in the physiopathology of a rare group of inflammatory diseases: ANCA associated vasculitis. Soluble CD95 Ligand might have a prognostic and diagnostic interest as well as potential for the discovery of new therapeutic strategies.

Completed

Looking for future studies?

Notify Me

Key information

About this study

ANCA associated vasculitis are a rare group of diseases and potentially life-threatening inflammatory conditions. There is an urgent need to describe prognostic factors and to discover new therapeutic pathways. Soluble CD95-L is a cleaved part of CD95-L which binds the CD95 Death receptor. s-CD95-L has pro-inflammatory properties for Th17 lymphocytes and Neutrophils, two cells implicated in ANCA associated vasculitis. It also plays a role in systemic lupus erythematosus (which present with the same type of renal glomerulonephritis as ANCA-associated vasculitis). Finally, it has already be found elevated in this group of diseases. The investigators hypothesized that s-CD95-L levels might be a prognostic factor in ANCA associated vasculitis and the study of the molecular mechanisms involved could provide new therapeutic targets.

The study will recruit 50 patients with ANCA associated vasculitis followed in Bordeaux University Hospital. Among classical disease activity information, blood and urine samples will be collected at each visit to study s-CD95-L. Fundamental research will be realized on patients' sample to study molecular mechanisms involved.

Clinical and biological disease activity, treatment and outcomes will be studied in correlation with s-CD95-L to describe their potential prognostic role. Patients will be followed at regular intervals, as their usual follow-up would request. No extra visit will be needed and blood samples will be drawn at the same time as those drawn for clinical purposes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of ANCA associated vasculitis according to the Chapel-Hill Consensus Conference - 2012 modified version
  • Age ≥ 18 years
  • being affiliated to health insurance
  • willing to participate and to sign informed consent.

Exclusion criteria

  • Pregnant or breastfeeding women,
  • patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)

Treatment and study plan

Blood sample

Biological

30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

urine sample

Biological

6 ml

Primary outcomes

  1. Change of quantitative levels of s-CD95-L in ANCA associated vasculitis between baseline and Month 12

    Time frame: At baseline (Day 0) and 12 months from baseline

Secondary outcomes

  1. Change of disease activity scores for ANCA associated vasculitis between baseline and Month 12

    Time frame: At baseline (Day 0) and 12 months from baseline

    Birmingham Vasculitis Activity Score - Version 3 (BVAS 3.0) The Birmingham Vasculitis Activity Score (BVAS) is a method for assessing the activity of vasculitis. Note that scoring ranges are higher when any of the features are new or worse. Creatinine levels can be scored at patient's first assessment only. The maximum score is 63 points for present symptoms and 32 points for new symptoms or symptoms which had worsened within the previous weeks.

  2. Change of disease activity scores for ANCA associated vasculitis between baseline and Month 12

    Time frame: At baseline (Day 0) and 12 months from baseline

    Vasculitis Damage Index (VDI)

  3. Change of quantification of s-CD95-L in the blood and urine samples of ANCA associated vasculitis between baseline and Month 12

    Time frame: At baseline (Day 0) and 12 months from baseline

  4. Change of quantification of ANCA in the blood samples of ANCA associated vasculitis between baseline and Month 12

    Time frame: At baseline (Day 0) and 12 months from baseline

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Collaborators

  • National Research Agency, France

Registry information

Official study title

Soluble CD95 Ligand Role in the Pathophysiology of ANCA Associated Vasculitis

Acronym: VASC-FAS

Important dates

Study start
2018
Primary completion
2024
Study completion
2024
First posted
Oct 5, 2018
Registry last updated
May 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.